Literature DB >> 15364053

Tolerance in mixed chimerism - a role for regulatory cells?

Josef Kurtz1, Thomas Wekerle, Megan Sykes.   

Abstract

The establishment of mixed hematopoietic chimerism induces life-long donor-specific organ graft tolerance while obviating the need for chronic immunosuppression. Recent advances have dramatically reduced the conditioning toxicity required to achieve mixed chimerism. We argue that the achievement of high levels of donor chimerism ensures life-long deletion of donor-reactive T cells, precluding and obviating the need for regulatory mechanisms in the maintenance of tolerance. However, in situations where high levels of donor chimerism cannot be established or sustained, control of immune responsiveness can be achieved through additional mechanisms, including regulatory T cells.

Entities:  

Mesh:

Year:  2004        PMID: 15364053     DOI: 10.1016/j.it.2004.08.007

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  28 in total

Review 1.  CD4(+)Foxp3(+) regulatory T cell therapy in transplantation.

Authors:  Qizhi Tang; Jeffrey A Bluestone; Sang-Mo Kang
Journal:  J Mol Cell Biol       Date:  2011-12-14       Impact factor: 6.216

Review 2.  Transplantation tolerance through mixed chimerism.

Authors:  Nina Pilat; Thomas Wekerle
Journal:  Nat Rev Nephrol       Date:  2010-08-31       Impact factor: 28.314

3.  Tolerization of a type I allergic immune response through transplantation of genetically modified hematopoietic stem cells.

Authors:  Ulrike Baranyi; Birgit Linhart; Nina Pilat; Martina Gattringer; Jessamyn Bagley; Ferdinand Muehlbacher; John Iacomini; Rudolf Valenta; Thomas Wekerle
Journal:  J Immunol       Date:  2008-06-15       Impact factor: 5.422

4.  Combining Treg therapy with mixed chimerism: Getting the best of both worlds.

Authors:  Nina Pilat; Thomas Wekerle
Journal:  Chimerism       Date:  2010 Jul-Sep

5.  Vascularized composite allotransplantation combined with costimulation blockade induces mixed chimerism and reveals intrinsic tolerogenic potential.

Authors:  Byoung Chol Oh; Georg J Furtmüller; Madeline L Fryer; Yinan Guo; Franka Messner; Johanna Krapf; Stefan Schneeberger; Damon S Cooney; W P Andrew Lee; Giorgio Raimondi; Gerald Brandacher
Journal:  JCI Insight       Date:  2020-04-09

6.  CTLA-4 on alloreactive CD4 T cells interacts with recipient CD80/86 to promote tolerance.

Authors:  Josef Kurtz; Forum Raval; Casey Vallot; Jayden Der; Megan Sykes
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

7.  Alloreactive CD8 T cell tolerance requires recipient B cells, dendritic cells, and MHC class II.

Authors:  Thomas Fehr; Fabienne Haspot; Joshua Mollov; Meredith Chittenden; Timothy Hogan; Megan Sykes
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

8.  Type 1 regulatory T cells are associated with persistent split erythroid/lymphoid chimerism after allogeneic hematopoietic stem cell transplantation for thalassemia.

Authors:  Giorgia Serafini; Marco Andreani; Manuela Testi; MariaRosa Battarra; Andrea Bontadini; Eika Biral; Katharina Fleischhauer; Sarah Marktel; Guido Lucarelli; Maria Grazia Roncarolo; Rosa Bacchetta
Journal:  Haematologica       Date:  2009-07-16       Impact factor: 9.941

9.  Direct and indirect antigen presentation lead to deletion of donor-specific T cells after in utero hematopoietic cell transplantation in mice.

Authors:  Amar Nijagal; Chris Derderian; Tom Le; Erin Jarvis; Linda Nguyen; Qizhi Tang; Tippi C Mackenzie
Journal:  Blood       Date:  2013-04-22       Impact factor: 22.113

10.  Anti-CD154 mAb and rapamycin induce T regulatory cell mediated tolerance in rat-to-mouse islet transplantation.

Authors:  Yannick D Muller; Gang Mai; Philippe Morel; Véronique Serre-Beinier; Carmen Gonelle-Gispert; Gisella Puga Yung; Driss Ehirchiou; Jean-Christophe Wyss; Sinda Bigenzahn; Magali Irla; Christoph Heusser; Déla Golshayan; Jörg D Seebach; Thomas Wekerle; Leo H Bühler
Journal:  PLoS One       Date:  2010-04-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.